Oct 26, 2020
Cingulate Therapeutics Presents Results of Pivotal Phase 2 Clinical Trial for Lead ADHD Candidate CTx-1301 at the American Association of Child and Adolescent Psychiatry Annual Meeting
Sep 07, 2018
BDD Pharma and Cingulate Therapeutics Announce License Agreement With OralogiK(TM) Enabled Triple Pulse Products
Jul 11, 2018
Cingulate Therapeutics Announces $7.5M Equity Investment from Werth Family Investment Associates
May 31, 2018
Cingulate Therapeutics Strengthens Leadership with Two New Board Appointments
Jan 15, 2018
Cingulate Therapeutics Presents New Data from its First in Human Proof of Concept Trial of CTX-1301 at the 2018 APSARD Annual Meeting
Jan 09, 2018
Cingulate Therapeutics Appoints Experienced Lead Investigator Matthew Brams, MD as Chief Medical Officer
Jan 04, 2018
Cingulate Therapeutics to Present New Data from its First in Human Proof of Concept Trial of CTX-1301 at the 2018 APSARD Annual Meeting
Dec 28, 2017
Cingulate Therapeutics to Present at 10th Annual Biotech Showcase
Nov 15, 2017
Cingulate Therapeutics to Present In Vivo Pharmacokinetic Data Demonstrating Consistent Tri-Phasic Release Profile of Lead Compound at the American Association of Pharmaceutical Scientists (AAPS) Annual Meeting
Aug 08, 2017
Cingulate Therapeutics Partners with Camargo Pharmaceutical Services for Development Programs
Jun 19, 2017
Cingulate Therapeutics to Present at 2017 Biotechnology Innovation Organization International Convention
Jun 15, 2017
Cingulate Therapeutics Announces Expansion to Accommodate Growth
May 31, 2017
Cingulate Therapeutics Initiates First Human Clinical Trial